How many sites of action for endocannabinoids to control energy metabolism?

[1]  M. Stock,et al.  Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice , 2005, International Journal of Obesity.

[2]  J. Herbert,et al.  The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile , 2005, Diabetes, obesity & metabolism.

[3]  Patrice D Cani,et al.  Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide , 2004, British Journal of Nutrition.

[4]  M. Korbonits,et al.  The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin , 2004, British journal of pharmacology.

[5]  M. Gil-Campos,et al.  Adiponectin, the missing link in insulin resistance and obesity. , 2004, Clinical nutrition.

[6]  I. McGregor,et al.  Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. , 2004, Endocrinology.

[7]  M. Tschöp,et al.  Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. , 2004, Endocrine reviews.

[8]  A. G. Roseberry,et al.  Rapid Rewiring of Arcuate Nucleus Feeding Circuits by Leptin , 2004, Science.

[9]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[10]  D. Thompson,et al.  Expression of Cannabinoid Cb1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin , 2022 .

[11]  J. Flier.  Obesity Wars Molecular Progress Confronts an Expanding Epidemic , 2004, Cell.

[12]  T. Horvath.  Endocannabinoids and the regulation of body fat: the smoke is clearing. , 2003, The Journal of clinical investigation.

[13]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[14]  R. Henry,et al.  Adiponectin: more than just another fat cell hormone? , 2003, Diabetes care.

[15]  Pierre Casellas,et al.  Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor , 2003, Journal of Biological Chemistry.

[16]  S. Di,et al.  Nongenomic Glucocorticoid Inhibition via Endocannabinoid Release in the Hypothalamus: A Fast Feedback Mechanism , 2003, The Journal of Neuroscience.

[17]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[18]  D. Cota,et al.  Endogenous cannabinoid system as a modulator of food intake , 2003, International Journal of Obesity.

[19]  S. Black,et al.  Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. , 2003, European journal of pharmacology.

[20]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[21]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[22]  V. Marzo,et al.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol , 2002, British journal of pharmacology.

[23]  N. Jamshidi,et al.  Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats , 2001, British journal of pharmacology.

[24]  A. Sanyal,et al.  Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis , 2001, Nature Medicine.

[25]  T. Kirkham,et al.  Endogenous cannabinoids and appetite , 2001, Nutrition Research Reviews.

[26]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[27]  L. Porrino,et al.  Effects of SR141716A on ethanol and sucrose self-administration. , 2001, Alcoholism, clinical and experimental research.

[28]  I. McGregor,et al.  The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716 , 1999, Psychopharmacology.

[29]  G. Gessa,et al.  Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. , 1998, Life sciences.

[30]  P. Soubrié,et al.  Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors , 1997, Psychopharmacology.

[31]  W. Powderly,et al.  Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. , 1997, Journal of pain and symptom management.

[32]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[33]  C. Geiger,et al.  Effect of Dronabinol on Nutritional Status in HIV Infection , 1993, The Annals of pharmacotherapy.

[34]  C. Baile,et al.  Oral and hypothalamic injections of barbiturates, benzodiazepines and cannabinoids and food intake in rats , 1979, Pharmacology Biochemistry and Behavior.

[35]  E. Abel.  Cannabis: effects on hunger and thirst. , 1975, Behavioral biology.

[36]  T. Kirkham,et al.  Synergistic efects of opioid and cannabinoid antagonists on food intake , 2000, Psychopharmacology.